Top-Rated StocksTop-RatedNASDAQ:RNA Avidity Biosciences (RNA) Stock Price, News & Analysis $47.52 -0.74 (-1.53%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$47.67 +0.15 (+0.32%) As of 08/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Avidity Biosciences Stock (NASDAQ:RNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avidity Biosciences alerts:Sign Up Key Stats Today's Range$46.05▼$48.1050-Day Range$28.40▼$48.2652-Week Range$21.51▼$56.00Volume4.31 million shsAverage Volume3.70 million shsMarket Capitalization$5.73 billionP/E RatioN/ADividend YieldN/APrice Target$66.35Consensus RatingBuy Company Overview Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. Read More Avidity Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreRNA MarketRank™: Avidity Biosciences scored higher than 55% of companies evaluated by MarketBeat, and ranked 438th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAvidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.06, and is based on 16 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvidity Biosciences has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Avidity Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($2.89) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -15.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -15.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvidity Biosciences has a P/B Ratio of 3.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avidity Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.49% of the outstanding shares of Avidity Biosciences have been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Avidity Biosciences has recently decreased by 2.75%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.49% of the outstanding shares of Avidity Biosciences have been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Avidity Biosciences has recently decreased by 2.75%, indicating that investor sentiment is improving. News and Social Media3.7 / 5News Sentiment0.59 News SentimentAvidity Biosciences has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Avidity Biosciences this week, compared to 8 articles on an average week.Search Interest20 people have searched for RNA on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.MarketBeat Follows8 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $957,260.00 in company stock.Percentage Held by InsidersOnly 3.83% of the stock of Avidity Biosciences is held by insiders.Read more about Avidity Biosciences' insider trading history. Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Stock News HeadlinesAvidity Biosciences, Inc. (NASDAQ:RNA) Insider John B. Moriarty Sells 2,245 SharesAugust 6 at 6:14 AM | insidertrades.comAvidity Biosciences Reports Second Quarter 2025 Financial Results and Recent HighlightsAugust 7 at 4:18 PM | prnewswire.comProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account. | Weiss Ratings (Ad)Novartis weighs deal for biotech Avidity Biosciences, FT reportsAugust 6 at 11:41 AM | reuters.comAvidity Biosciences (RNA) Expected to Announce Earnings on FridayAugust 6 at 3:43 AM | americanbankingnews.comWe Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business GrowthJuly 31, 2025 | finance.yahoo.comAvidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory SubmissionJuly 28, 2025 | prnewswire.comAvidity (RNA) Jumps 9.2% on Drug Candidate’s Breakthrough Therapy DesignationJuly 26, 2025 | msn.comSee More Headlines RNA Stock Analysis - Frequently Asked Questions How have RNA shares performed this year? Avidity Biosciences' stock was trading at $29.08 at the beginning of 2025. Since then, RNA shares have increased by 63.4% and is now trading at $47.52. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) issued its earnings results on Thursday, May, 8th. The biotechnology company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by $0.02. The biotechnology company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.63 million. Avidity Biosciences had a negative net margin of 4,136.00% and a negative trailing twelve-month return on equity of 26.96%. When did Avidity Biosciences IPO? Avidity Biosciences (RNA) raised $150 million in an initial public offering on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO. Who are Avidity Biosciences' major shareholders? Top institutional investors of Avidity Biosciences include TD Asset Management Inc (0.34%), Bank of New York Mellon Corp (0.32%), Mutual of America Capital Management LLC (0.15%) and EFG Asset Management North America Corp. (0.14%). Insiders that own company stock include Sarah Boyce, Teresa Mccarthy, Michael F Maclean, W Michael Flanagan, Steven George Hughes, Kathleen P Gallagher, John B Moriarty, Arthur A Levin and Tamar Thompson. View institutional ownership trends. How do I buy shares of Avidity Biosciences? Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avidity Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Eli Lilly and Company (LLY), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/08/2025Today8/08/2025Next Earnings (Estimated)8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNA CIK1599901 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees190Year FoundedN/APrice Target and Rating Average Price Target for Avidity Biosciences$66.35 High Price Target$96.00 Low Price Target$50.00 Potential Upside/Downside+39.6%Consensus RatingBuy Rating Score (0-4)3.06 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($3.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$322.30 million Net Margins-4,136.00% Pretax Margin-4,135.99% Return on Equity-26.96% Return on Assets-24.57% Debt Debt-to-Equity RatioN/A Current Ratio16.91 Quick Ratio16.91 Sales & Book Value Annual Sales$10.90 million Price / Sales525.42 Cash FlowN/A Price / Cash FlowN/A Book Value$11.94 per share Price / Book3.98Miscellaneous Outstanding Shares120,520,000Free Float115,904,000Market Cap$5.73 billion OptionableOptionable Beta0.95 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:RNA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.